Clinical trials: Drug-Drug Interactions
Type 2 Diabetes Mellitus
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
A Clinical trial to investigate the pharmacokinetic drug interaction and safety of CKD-501, D759 and D150
- Trial name
- NCT04431687
- Testing
- CKD 501, D759, D150, CKD-501, D759, D150
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy
A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately
The purpose of the study is to assess whether there is any pharmacokinetic interactions between CAZ-AVI and metronidazole.
- Trial name
- NCT01534247
- Testing
- CAZ-AVI, metronidazole, CAZ-AVI + metronidazole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects
Drug-drug Interaction Study with TS-142 in Healthy Adult Subjects (concomitant Administration of Itraconazole)
This is an open-label, single-center, single-sequence study to evaluate the concomitant effects of the potent CYP3A inhibitor itraconazole on the single-dose pharmakokinetics, safety and tolerability of oral TS-142 in healthy…
- Trial name
- NCT04557163
- Testing
- TS-142, Itraconazole
- Where
- Japan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Infections, Bacterial
Relative Bioavailability Study in Healthy Subjects
Part 1 of this study will assess the relative bioavailability of GSK1322322 administered as one of three investigational tablets compared to powder in a bottle formulation.
- Trial name
- PDF112034 (NCT00924911)
- Testing
- GSK1322322
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Subjects
Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects
The primary objective is to evaluate the effect of rifampin, a potent cytochrome P450 3A4 inducer, at steady-state on the systemic exposure of a single dose of pacritinib in healthy subjects.
- Trial name
- NCT02807116
- Testing
- Pacritinib, Rifampin, Pacritinib and Rifampin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Drug Drug Interaction
Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects
To evaluate the effect of coadministered cyclosporine on the pharmacokinetics of brincidofovir following simultaneous administration of SyB V-1901 with cyclosporine, or coadministration of cyclosporine at 2 hours after the…
- Trial name
- NCT04542252
- Testing
- SyB V-1901, Cyclosporine
- Where
- Japan
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- SymBio Pharmaceuticals
Healthy
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)
The goal of this study is to learn what happens to a single dose of alendronate over time in a healthy participant's body when the participant is given a single dose of enlicitide decanoate.
- Trial name
- NCT06772792
- Testing
- Alendronate, Enlicitide Decanoate
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Subjects, Drug-drug Interaction, Pyrotinib
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
This drug-drug interaction (DDI) study had been designed to investigate the effect of a moderate CYP 3A inducer efavirenz on the pharmacokinetics of maleate pyrotinib in Chinese healthy volunteers.
- Trial name
- NCT04680091
- Testing
- Pyrotinib Maleate, Efavirenz
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Participants
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
The primary objective of the trial is to assess the effect of multiple doses of the cytochrome P450 (CYP3A4) enzyme inducer carbamazepine (Part A) or the CYP3A4 inhibitor itraconazole (Part B) on the single-dose pharmacokinetics…
- Trial name
- NCT07449390
- Testing
- AP31969, Carbamazepine, Itraconazole
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Acesion Pharma
Chronic Kidney Disease
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
This Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK).
- Trial name
- NCT04532918
- Testing
- Verinurad, Allopurinol, Cyclosporine
- Where
- Germany
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI
Evaluation and validation of metabolic markers for the assessment of CYP3A activity and prediction of drug-drug interaction in Korean healthy subjects.
- Trial name
- CYP3A_weak (NCT02328443)
- Testing
- Midazolam, itraconazole, rifampicin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy, Food-drug Interaction
Relacorilant Food Effect Study in Healthy Subjects
This is an open-label, randomized, single-dose, 3-period crossover, Williams' design, food-interaction (fasted and fed arms) study conducted in healthy subjects.
- Trial name
- NCT03442621
- Testing
- Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Hepatitis C, HIV
Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers
The investigators believe that boceprevir's drug concentrations will be reduced when administered in combination with etravirine.
- Trial name
- NCT01427504
- Testing
- boceprevir; etravirine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type II
Bioequivalence Study for Acarbose / Metformin FDC
To establish the bioequivalence between Acarbose / Metformin FDC (50mg / 500mg) and loose combination of Acarbose (Glucobay) (50mg) and Metformin (Glucophage) (500mg).
- Trial name
- NCT01728740
- Testing
- Acarbose/Metformin FDC (BAY81-9783), Acarbose (Glucobay, BAYG5421), Metformin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bayer
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B.
- Trial name
- NCT06491550
- Testing
- AZD4144- Part A, AZD4144- Part B, Rosuvastatin and Furosemide- Part C
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Drug-Drug Interaction Study: ASP2151 and Midazolam
CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the induction effect of ASP2151 on that enzyme to determine the extent of any possible drug interactions.
- Trial name
- NCT02403635
- Testing
- Midazolam, ASP2151
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Maruho Europe Limited
Drug Drug Interaction
Fruquintinib CYP3A Inhibitor and Inducer Study
A study to assess the effect of itraconazole, a strong CYP3A inhibitor, and the effect of rifampin, a strong CYP3A inducer, on the pharmacokinetics of fruquintinib in healthy subjects.
- Trial name
- NCT04557397
- Testing
- Fruquintinib, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hutchison Medipharma Limited
Pain
A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin
The purpose of this study is to evaluate the pharmacokinetics of midazolam and digoxin in the absence and presence of VX-548.
- Trial name
- NCT05541471
- Testing
- VX-548, Midazolam, Digoxin
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Drug Drug Interaction, Healthy
Pharmacokinetics of Omeprazole and Midazolam When Co-administered With ACT-1014-6470
A study on whether ACT-1014-6470 has an effect on how the body takes up, distributes and gets rid of omeprazole and midazolam in healthy male subjects
- Trial name
- NCT05123820
- Testing
- Treatment period A, Treatment period B
- Where
- Czechia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Healthy Volunteer
Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers
This trial will consist of three parts: the first two parts will enroll healthy female volunteers into a single ascending dose (SAD) and multiple ascending dose (MAD) treatment groups.
- Trial name
- NCT02846142
- Testing
- PTI-428, ethinyl estradiol and levonorgestrel
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Proteostasis Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.